Aspiration risk increases in any sedated patient, but emergency anesthesia teams have protocols for people on GLP-1 therapy
While bloating may not appear as a distinct adverse event term in clinical trial data, it often occurs alongside documented side effects such as nausea, vomiting, constipation, and dyspepsia
Its appetite-suppressing prowess is exhibited in its GLP 1 biochemical properties, whereas gastric inhibitory polypeptide (GIP), a gut hormone, helps suppress emptying of the stomach
Volpe S, Lisco G, Fanelli M, Racaniello D, Colaianni V, Triggiani D, et al
That scale would theoretically generate a real-world evidence dataset large enough to detect rare adverse drug events at statistically meaningful rates
In Retatrutide trials, 7% of participants stopped treatment due to side effects at the 12mg dose